Merck jumps as it launches tender offer for $6.7B Terns oncology buyout
Merck shares rose after the company began a cash tender offer to acquire Terns Pharmaceuticals for $53 per share, advancing its $6.7 billion oncology deal. Investors are treating the formal launch of the tender as a key step toward closing the transaction and strengthening Merck’s post-2028 pipeline plans.
1) What’s moving the stock
Merck is trading higher today after it formally launched the tender offer process to acquire Terns Pharmaceuticals in an all-cash deal priced at $53.00 per share. The tender-offer start is a concrete closing milestone—moving the transaction from announcement phase into execution—and it reinforces Merck’s push to add oncology pipeline assets ahead of looming exclusivity pressure on its biggest product later this decade. �citeturn1search0turn1news12
2) Deal terms and why the market cares
Merck’s agreed transaction values Terns at about $6.7 billion and is structured to close via a tender offer followed by a merger, subject to customary conditions including sufficient shares being tendered. For Merck investors, the near-term focus is less about immediate earnings accretion and more about strategic pipeline depth—particularly as the industry models Merck’s revenue trajectory through major patent events. �citeturn1news12turn1search0
3) What to watch next
The next catalysts are tender-offer progress updates, any amendments to timing/conditions, and further detail on how Merck plans to integrate and prioritize Terns’ programs within its oncology R&D portfolio. Separately, investors will keep tracking additional regulatory and clinical readouts tied to Keytruda’s lifecycle expansion, which can influence sentiment on Merck’s longer-run oncology growth bridge. �citeturn1search0turn1search10